Reagent: Antiserum to HTLV-I Sp-2, 3/4A Peptides

Catalog Number: 1578

Lot Number: 3 8/11/92

Provided: 1 ml unfiltered antiserum.

Host or Host Site: Goat.

Titer: 90% syncytia inhibition is seen at 1:160. Syncytium formation assays were performed as described in Palker et al., 1992. Briefly, 45 µl each of HTLV-I+ C91/PL T cells and uninfected C8166 cells (1 x 10^6 cells/ml) are added to the wells of a microtiter plate containing 10 µl of heat-inactivated test or control serum. Plates are incubated for 24 hours at 37°C in a 5% CO₂ incubator, then examined for syncytia formation.

Special Characteristics: Antiserum was raised against the synthetic HTLV-I envelope peptides SP-2 and SP-3/4A coupled to tetanus toxoid. Most of the neutralizing activity is directed against SP-2 (aa 86-107). SP-3 corresponds to aa 176-189 and SP-4 to aa 190-209. The antiserum should be heat-inactivated at 56°C for 30 minutes prior to use in neutralization assays. Anti SP-2, SP-3/4A does not cross neutralize HTLV-II.

Recommended Storage: Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Thomas J. Palker.


NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Antiserum to HTLV-I Sp-2, 3/4A from Dr. Thomas Palker." Also include the reference cited above in any publications.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.
ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.